Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

About Eagle Pharmaceuticals

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EGRX
  • CUSIP:
Key Metrics:
  • Previous Close: $73.59
  • 50 Day Moving Average: $70.14
  • 200 Day Moving Average: $69.00
  • 52-Week Range: $33.02 - $87.78
  • Trailing P/E Ratio: 47.01
  • Foreward P/E Ratio: 15.30
  • P/E Growth: 1.19
  • Market Cap: $1.11B
  • Outstanding Shares: 15,435,000
  • Beta: 1.54
Profitability:
  • Net Margins: 20.06%
  • Return on Equity: 25.63%
  • Return on Assets: 18.48%
Debt:
  • Current Ratio: 3.36%
  • Quick Ratio: 3.16%
Additional Links:
Companies Related to Eagle Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Eagle Pharmaceuticals (NASDAQ:EGRX) (?)
Ratings Breakdown: 1 Sell Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $86.20 (19.37% upside)

Analysts' Ratings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Show:
DateFirmActionRatingPrice TargetDetails
1/9/2017RBC Capital MarketsReiterated RatingOutperform$93.00 -> $86.00View Rating Details
1/9/2017MizuhoDowngradeNeutral -> Underperform$78.00 -> $64.00View Rating Details
11/3/2016Royal Bank Of CanadaBoost Price TargetOutperform$80.00 -> $93.00View Rating Details
11/2/2016William BlairBoost Price TargetOutperform$83.00 -> $97.00View Rating Details
10/15/2016Piper Jaffray CompaniesReiterated RatingBuy$91.00View Rating Details
7/2/2015Cantor FitzgeraldReiterated RatingBuy$95.00 -> $92.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
11/9/2016Q316$0.61$0.73$41.04 million$37.80 millionViewListenView Earnings Details
8/9/2016Q216$0.71$0.80$43.55 million$40.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.30$0.07$20.78 million$18.20 millionViewListenView Earnings Details
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details
8/11/2015Q215($0.57)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details
5/12/2015Q115$1.47$1.31$3.41 million$36.30 millionViewListenView Earnings Details
2/17/2015($0.49)($0.47)ViewN/AView Earnings Details
12/17/2014Q314($0.49)($0.65)$2.81 millionViewN/AView Earnings Details
8/11/2014Q214($0.37)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)
Current Year EPS Consensus Estimate: $4.12 EPS
Next Year EPS Consensus Estimate: $4.72 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.02$0.02$0.02
Q2 20161$0.78$0.78$0.78
Q3 20161$0.85$0.85$0.85
Q4 20161$2.70$2.70$2.70
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Insider Ownership Percentage: 18.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Proquest Investments Iv, L.P.Major ShareholderSell65,114$85.16$5,545,108.24View SEC Filing  
12/13/2016Steven B RatoffDirectorSell10,000$75.01$750,100.00View SEC Filing  
11/28/2016Sander A FlaumDirectorSell5,000$78.66$393,300.00View SEC Filing  
11/11/2016Proquest Investments Iv, L.P.Major ShareholderSell34,486$85.15$2,936,482.90View SEC Filing  
11/9/2016Proquest Investments Iv, L.P.Major ShareholderSell153,830$79.29$12,197,180.70View SEC Filing  
11/7/2016Proquest Investments Iv, L.P.Major ShareholderSell5,030$75.39$379,211.70View SEC Filing  
11/4/2016Proquest Investments Iv, L.P.Major ShareholderSell245,770$71.02$17,454,585.40View SEC Filing  
9/30/2016Proquest Investments Iv, L.P.Major ShareholderSell22,100$70.06$1,548,326.00View SEC Filing  
9/29/2016Proquest Investments Iv, L.P.Major ShareholderSell77,900$70.04$5,456,116.00View SEC Filing  
9/21/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$66.17$6,603,435.15View SEC Filing  
9/8/2016Proquest Investments Iv, L.P.Major ShareholderSell70,925$62.50$4,432,812.50View SEC Filing  
8/24/2016Proquest Investments Iv, L.P.Major ShareholderSell28,870$63.00$1,818,810.00View SEC Filing  
8/17/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$61.36$6,123,421.20View SEC Filing  
8/16/2016Proquest Investments Iv, L.P.Major ShareholderSell60,150$61.67$3,709,450.50View SEC Filing  
8/15/2016Proquest Investments Iv, L.P.Major ShareholderSell24,949$60.77$1,516,150.73View SEC Filing  
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.95View SEC Filing  
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.00View SEC Filing  
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.80View SEC Filing  
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.25View SEC Filing  
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.50View SEC Filing  
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.57View SEC Filing  
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.76View SEC Filing  
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.75View SEC Filing  
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateHeadline
us.rd.yahoo.com logoEagle Pharmaceuticals Announces New Patents Issued for Bendeka (NASDAQ:EGRX)
us.rd.yahoo.com - February 22 at 5:12 PM
News IconBrokerage Firm Target Review on Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Rockville Register (NASDAQ:EGRX)
rockvilleregister.com - February 22 at 7:17 AM
businesswire.com logoEagle Pharmaceuticals Announces New Patents Issued for Bendeka - Business Wire (press release) (NASDAQ:EGRX)
www.businesswire.com - February 22 at 7:17 AM
News IconEagle Pharmaceuticals Inc EGRX Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:EGRX)
www.bioportfolio.com - February 18 at 4:37 PM
News IconIs The Sell-Side Predicting That Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Will Move Higher? - Winfield Review (NASDAQ:EGRX)
winfieldreview.com - February 18 at 10:48 AM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2016 Financial Results on March 1, 2017 (NASDAQ:EGRX)
finance.yahoo.com - February 16 at 8:22 AM
News IconAre Analysts Optimistic About Where Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is Heading? - Winfield Review (NASDAQ:EGRX)
winfieldreview.com - February 15 at 8:47 PM
News IconEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Bearish Target At $98 - Stock Observer (NASDAQ:EGRX)
www.thestockobserver.com - February 15 at 8:47 PM
4-traders.com logoEagle Pharmaceuticals : to Present at 2017 RBC Capital Markets Global Healthcare Conference (NASDAQ:EGRX)
www.4-traders.com - February 14 at 5:50 PM
finance.yahoo.com logoEagle Pharmaceuticals to Present at 2017 RBC Capital Markets Global Healthcare Conference (NASDAQ:EGRX)
finance.yahoo.com - February 13 at 5:39 PM
News IconQuarterly EPS Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Set At $2.5 - Stock Observer (NASDAQ:EGRX)
www.thestockobserver.com - February 11 at 4:59 PM
News IconChecking the Charts on Shares of Eagle Pharmaceuticals Inc. (EGRX) - Benton Bulletin (NASDAQ:EGRX)
bentonbulletin.com - February 9 at 5:28 PM
biz.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fina (NASDAQ:EGRX)
biz.yahoo.com - February 8 at 5:25 PM
biz.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits (NASDAQ:EGRX)
biz.yahoo.com - February 8 at 5:25 PM
News IconEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Daily Sentiment Score At 0.31 - Stock Observer (NASDAQ:EGRX)
www.thestockobserver.com - February 6 at 9:59 PM
4-traders.com logoEagle Pharmaceuticals : How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma (NASDAQ:EGRX)
www.4-traders.com - February 3 at 5:18 PM
News IconStock Vacillating as Volatility Hits a High Point For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Wall Street Beacon (NASDAQ:EGRX)
wsbeacon.com - January 31 at 5:36 PM
News IconSell-side is Weighing in on Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Earnings & Targets - Aiken Advocate (NASDAQ:EGRX)
aikenadvocate.com - January 26 at 6:13 PM
finance.yahoo.com logoFalling Earnings Estimates Signal Weakness Ahead for Eagle Pharmaceuticals (EGRX) - Yahoo Finance (NASDAQ:EGRX)
finance.yahoo.com - January 26 at 6:13 PM
finance.yahoo.com logoEagle Pharmaceuticals Wraps Up Ryanodex NDA Submission (NASDAQ:EGRX)
finance.yahoo.com - January 24 at 5:34 PM
streetinsider.com logoEagle Pharmaceuticals (EGRX) Completes NDA Submission for Ryanodex (NASDAQ:EGRX)
www.streetinsider.com - January 23 at 5:16 PM
finance.yahoo.com logoEagle Pharmaceuticals Completes NDA Submission for Ryanodex for Exertional Heat Stroke to FDA (NASDAQ:EGRX)
finance.yahoo.com - January 23 at 9:03 AM
News IconAmplified Volatility Spotted in Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Wall Street Beacon (NASDAQ:EGRX)
wsbeacon.com - January 19 at 6:22 PM
News IconRunning on Fumes? Stock Sluggish Out of the Gate: Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Aiken Advocate (NASDAQ:EGRX)
aikenadvocate.com - January 17 at 8:19 PM
News IconWill The Needle Move For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:EGRX)
wsbeacon.com - January 17 at 8:03 AM
News IconStock Mounting Higher Mid-Session: Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Wall Street Beacon (NASDAQ:EGRX)
wsbeacon.com - January 12 at 5:22 PM
biz.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:EGRX)
biz.yahoo.com - January 11 at 5:27 PM
nasdaq.com logoNotable Tuesday Option Activity: AVGO, EGRX, HD (NASDAQ:EGRX)
www.nasdaq.com - January 10 at 5:51 PM
capitalcube.com logoEagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : January 10, 2017 (NASDAQ:EGRX)
us.rd.yahoo.com - January 10 at 5:51 PM
smarteranalyst.com logoTop Mizuho Analyst Sounds the Alarm on Eagle Pharmaceuticals Inc (EGRX) and Cuts Price Target; Shares Plunge 13% - Smarter Analyst (NASDAQ:EGRX)
www.smarteranalyst.com - January 10 at 3:45 AM
smarteranalyst.com logoTop Mizuho Analyst Sounds the Alarm on Eagle Pharmaceuticals Inc (EGRX) and Cuts Price Target; Shares Plunge 13% (NASDAQ:EGRX)
www.smarteranalyst.com - January 9 at 10:43 PM
News IconEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Daily Sentiment Score At 0.252 - Stock Observer (NASDAQ:EGRX)
www.thestockobserver.com - January 9 at 5:42 PM
finance.yahoo.com logoEagle Pharma downgraded by Mizuho (NASDAQ:EGRX)
finance.yahoo.com - January 9 at 5:42 PM
capitalcube.com logoEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : January 9, 2017 (NASDAQ:EGRX)
www.capitalcube.com - January 9 at 5:42 PM
News IconEagle Pharmaceuticals Inc EGRX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:EGRX)
www.bioportfolio.com - January 8 at 9:48 PM
News IconQuarterly EPS Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) At $2.73 - Stock Observer (NASDAQ:EGRX)
www.thestockobserver.com - January 7 at 5:49 PM
biz.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:EGRX)
biz.yahoo.com - January 6 at 5:27 PM
streetinsider.com logoEagle Pharmaceuticals (EGRX) Submits Pemetrexed NDA (NASDAQ:EGRX)
www.streetinsider.com - January 4 at 11:03 PM
News IconEagle Pharmaceuticals Pemetrexed NDA Submitted for Review (NASDAQ:EGRX)
www.cbs58.com - January 4 at 6:01 PM
finance.yahoo.com logoEagle Pharmaceuticals to Present at J.P. Morgan 35th Annual Healthcare Conference (NASDAQ:EGRX)
finance.yahoo.com - January 4 at 6:01 PM
investornewswire.com logoEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:EGRX)
www.investornewswire.com - January 3 at 11:51 PM
streetinsider.com logoEagle Pharmaceuticals (EGRX) Submits Pemetrexed NDA - StreetInsider.com (NASDAQ:EGRX)
www.streetinsider.com - January 3 at 6:50 PM
publicnow.com logoEagle Pharmaceuticals’ Pemetrexed NDA Submitted for Review (NASDAQ:EGRX)
www.publicnow.com - January 3 at 12:23 PM
4-traders.com logoEagle Pharmaceuticals : Bank of Montreal Can Has $8,479,000 Position in Eagle Pharmaceuticals Inc. (EGRX) (NASDAQ:EGRX)
www.4-traders.com - December 27 at 11:47 AM
streetinsider.com logoEagle Pharmaceuticals (EGRX) Names David Pernock as President and CCO - StreetInsider.com (NASDAQ:EGRX)
www.streetinsider.com - December 20 at 11:47 PM
us.rd.yahoo.com logo8:04 am Eagle Pharma appoints David Pernock as President and Chief Commercial Officer, effective January 2017 (NASDAQ:EGRX)
us.rd.yahoo.com - December 20 at 9:56 AM
biz.yahoo.com logoEAGLE PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, (NASDAQ:EGRX)
biz.yahoo.com - December 20 at 9:56 AM
forbes.com logoNotable Friday Option Activity: EGRX, VTR, CPN (NASDAQ:EGRX)
www.forbes.com - December 16 at 5:26 PM
News IconEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Bearish Target At $102 - Stock Observer (NASDAQ:EGRX)
www.thestockobserver.com - December 15 at 6:24 AM
insidermonkey.com logoIs Eagle Pharmaceuticals Inc (EGRX) A Good Stock To Buy? (NASDAQ:EGRX)
www.insidermonkey.com - December 13 at 5:34 PM

Social

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Where is Eagle Pharmaceuticals' stock going? Where will Eagle Pharmaceuticals' stock price be in 2017?

5 brokers have issued twelve-month price targets for Eagle Pharmaceuticals' stock. Their forecasts range from $64.00 to $97.00. On average, they expect Eagle Pharmaceuticals' share price to reach $86.20 in the next twelve months.

When will Eagle Pharmaceuticals announce their earnings?

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

Who owns Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ProQuest Associates IV LLC (25.60%), Janus Capital Management LLC (9.62%), Orbimed Advisors LLC (4.35%), State Street Corp (4.23%), JW Asset Management LLC (3.41%) and Perceptive Advisors LLC (3.23%). Company insiders that own Eagle Pharmaceuticals stock include Michael Graves, Proquest Investments Iv, LP, Proquest Management Llc, Sander A Flaum, Sander A Flaum, Scott Tarriff, Steven B Ratoff and Steven L Krill.

Who sold Eagle Pharmaceuticals stock? Who is selling Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including ProQuest Associates IV LLC, Orbimed Advisors LLC, Janus Capital Management LLC, Guggenheim Capital LLC, Opaleye Management Inc., Ranger Investment Management L.P., Allianz Asset Management AG and Kopp Investment Advisors LLC. Company insiders that have sold Eagle Pharmaceuticals stock in the last year include Proquest Investments Iv, LP, Proquest Management Llc, Sander A Flaum, Scott Tarriff and Steven B Ratoff.

Who bought Eagle Pharmaceuticals stock? Who is buying Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Castleark Management LLC, State Street Corp, FMR LLC, Nicholas Investment Partners LP, Baird Financial Group Inc., Two Sigma Investments LP and Russell Investments Group Ltd..

How do I buy Eagle Pharmaceuticals stock?

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eagle Pharmaceuticals stock cost?

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $72.21.

Eagle Pharmaceuticals (NASDAQ:EGRX) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Earnings History Chart

Earnings by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Dividend History Chart

Dividend Payments by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Last Updated on 2/23/2017 by MarketBeat.com Staff